We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

109 hedge funds and large institutions have $495M invested in Albireo Pharma Inc in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 39 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,633% more call options, than puts

Call options by funds: $8.42M | Put options by funds: $486K

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

37% more capital invested

Capital invested by funds: $362M → $495M (+$133M)

14% more funds holding

Funds holding: 96 → 109 (+13)

23% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 39

Holders
109
Holders Change
+13
Holders Change %
+13.54%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
21
Increased
30
Reduced
39
Closed
8
Calls
$8.42M
Puts
$486K
Net Calls
+$7.93M
Net Calls Change
+$6.83M

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$13.7M
2
NIP
Nicholas Investment Partners
California
+$12.9M
3
O
OrbiMed
New York
+$5.68M
4
Franklin Resources
Franklin Resources
California
+$5.1M
5
CC
Chicago Capital
Illinois
+$4.76M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$14M
2
Millennium Management
Millennium Management
New York
-$4.6M
3
Goldman Sachs
Goldman Sachs
New York
-$3.75M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.01M
5
State Street
State Street
Massachusetts
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$3.01M +$2.49M +84,900 +534%
SB
27
Samsara BioCapital
California
$2.98M – – –
Citadel Advisors
28
Citadel Advisors
Florida
$2.92M +$2.02M +69,163 +240%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.88M +$369K +12,600 +15%
PPA
30
Parametric Portfolio Associates
Washington
$1.9M +$526K +17,969 +39%
Millennium Management
31
Millennium Management
New York
$1.81M -$4.6M -157,145 -72%
William Blair & Company
32
William Blair & Company
Illinois
$1.67M -$497K -16,967 -23%
Morgan Stanley
33
Morgan Stanley
New York
$1.62M +$413K +14,107 +35%
BGIM
34
Brandywine Global Investment Management
Pennsylvania
$1.5M – – –
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.49M -$416K -14,203 -22%
Bank of America
36
Bank of America
North Carolina
$1.46M -$511K -17,442 -26%
N
37
Nuveen
North Carolina
$1.41M -$121K -4,130 -8%
Charles Schwab
38
Charles Schwab
California
$1.38M +$11K +375 +0.8%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$1.32M -$55.6K -1,900 -4%
Goldman Sachs
40
Goldman Sachs
New York
$1.29M -$3.75M -128,140 -75%
UBS Group
41
UBS Group
Switzerland
$1.23M +$755K +25,796 +166%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.16M +$82K +2,800 +8%
AC
43
Apogem Capital
New York
$1.06M -$91.1K -3,113 -8%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$871K +$511K +17,451 +149%
SOS
45
Silver Oak Securities
Tennessee
$836K +$697K +23,795 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$716K -$633K -21,632 -47%
AllianceBernstein
47
AllianceBernstein
Tennessee
$683K +$2.93K +100 +0.4%
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$680K – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$643K -$41K -1,399 -6%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$613K -$236K -8,070 -28%
1
2
3 4 5

ALBO Hedge Fund Activity: Q1 2022 in Review

109 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2022, worth a combined $495M — up 37% from $362M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ALBO positions and 8 closed out — a net gain of 13 holders — while 30 added to existing stakes and 39 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.7M. The largest seller was Artal Group, exiting entirely with an estimated $14M sold.

  • 109 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2022, up from 96 in Q4 2021.
  • Funds reported $495M of Albireo Pharma Inc stock for Q1 2022, up 37% quarter-over-quarter.
  • 21 funds opened new Albireo Pharma Inc positions in Q1 2022 and 8 closed out, a net change of +13 holders.
  • The largest Albireo Pharma Inc buyer in Q1 2022 was Tang Capital Management, an estimated $13.7M added.
  • The largest Albireo Pharma Inc seller in Q1 2022 was Artal Group, an estimated $14M sold.

Based on aggregated 13F filings for Q1 2022.